Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Assets (2022 - 2025)

Historic Assets for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $360.3 million.

  • Stoke Therapeutics' Assets rose 2282.33% to $360.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.3 million, marking a year-over-year increase of 2282.33%. This contributed to the annual value of $271.6 million for FY2024, which is 1892.47% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Assets of $360.3 million as of Q3 2025, which was up 2282.33% from $384.5 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Assets high stood at $406.9 million for Q1 2025, and its period low was $205.2 million during Q1 2024.
  • Its 4-year average for Assets is $292.5 million, with a median of $281.8 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first tumbled by 2718.78% in 2024, then surged by 9830.59% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Assets (Quarter) stood at $256.1 million in 2022, then dropped by 10.83% to $228.3 million in 2023, then rose by 18.92% to $271.6 million in 2024, then skyrocketed by 32.67% to $360.3 million in 2025.
  • Its Assets stands at $360.3 million for Q3 2025, versus $384.5 million for Q2 2025 and $406.9 million for Q1 2025.